News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
566,301 Results
Type
Article (50392)
Company Profile (131)
Press Release (515778)
Section
Business (155889)
Career Advice (2451)
Deals (29085)
Drug Delivery (120)
Drug Development (71430)
Employer Resources (151)
FDA (15818)
Job Trends (12569)
News (279740)
Policy (30563)
Tag
Academia (2646)
Alliances (39944)
Alzheimer's disease (1426)
Approvals (15767)
Artificial intelligence (202)
Bankruptcy (313)
Best Places to Work (9739)
Breast cancer (223)
Cancer (1687)
Cardiovascular disease (137)
Career advice (2048)
CAR-T (127)
Cell therapy (355)
Clinical research (57324)
Collaboration (617)
Compensation (370)
COVID-19 (2630)
C-suite (158)
Data (1544)
Diabetes (214)
Diagnostics (5589)
Earnings (59510)
Employer resources (139)
Events (81841)
Executive appointments (522)
FDA (16717)
Funding (564)
Gene therapy (262)
GLP-1 (724)
Government (3995)
Healthcare (16045)
Infectious disease (2746)
Inflammatory bowel disease (120)
Interviews (449)
IPO (14353)
Job creations (3251)
Job search strategy (1710)
Layoffs (483)
Legal (7182)
Lung cancer (249)
Manufacturing (231)
Medical device (11568)
Medtech (11571)
Mergers & acquisitions (15093)
Metabolic disorders (595)
Neuroscience (1848)
NextGen: Class of 2025 (5359)
Non-profit (3747)
Northern California (1972)
Obesity (342)
Opinion (220)
Parkinson's disease (116)
Patents (161)
People (46501)
Phase I (17379)
Phase II (24922)
Phase III (19944)
Pipeline (719)
Postmarket research (2332)
Preclinical (7163)
Radiopharmaceuticals (221)
Rare diseases (340)
Real estate (4676)
Regulatory (21191)
Research institute (2462)
Resumes & cover letters (408)
Southern California (1648)
Startups (3035)
United States (16914)
Vaccines (692)
Weight loss (261)
Date
Last 7 days (577)
Last 30 days (2371)
Last 365 days (32037)
2025 (4237)
2024 (32644)
2023 (36457)
2022 (46794)
2021 (50506)
2020 (47766)
2019 (38964)
2018 (29490)
2017 (29384)
2016 (27842)
2015 (30549)
2014 (24106)
2013 (19975)
2012 (21312)
2011 (21661)
2010 (19655)
Location
Africa (727)
Arizona (162)
Asia (33614)
Australia (6043)
California (4403)
Canada (1362)
China (324)
Colorado (195)
Connecticut (227)
Europe (80543)
Florida (657)
Georgia (145)
Illinois (398)
Indiana (231)
Maryland (719)
Massachusetts (3337)
Michigan (162)
Minnesota (285)
New Jersey (1256)
New York (1236)
North Carolina (795)
Northern California (1972)
Ohio (152)
Pennsylvania (992)
South America (1103)
Southern California (1648)
Texas (640)
Utah (125)
Washington State (431)
566,301 Results for "banner alzheimer s institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.
January 23, 2025
·
2 min read
·
Dan Samorodnitsky
GLP-1
Evidence Mounts for Potential of GLP-1s in Alzheimer’s Disease
The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.
December 9, 2024
·
6 min read
·
Heather McKenzie
Neurodegenerative disease
7 Alzheimer’s and Parkinson’s Programs Discarded in 2024
This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are still chasing these multi-billion-dollar markets.
November 4, 2024
·
6 min read
·
Heather McKenzie
Alzheimer’s disease
Cassava’s Shares Plunge as Alzheimer’s Drug Fails Phase III
Cassava Sciences has revealed the late-stage clinical failure of controversial Alzheimer’s drug simulfilam. The company had pledged to share the results whether “good, bad or ambiguous.”
November 25, 2024
·
2 min read
·
Annalee Armstrong
Press Releases
Cycle Pharma Acquires Banner Life Sciences, LLC
January 13, 2025
·
17 min read
Podcast
BridgeBio’s ATTR-CM Approval, Cassava’s Alzheimer’s Failure, Trump’s Cabinet Picks, More
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for Amvuttra in the indication; Cassava’s controversial Alzheimer’s drug flunks Phase III; Amgen’s MariTide fails to impress investors, Donald Trump’s controversial nominations continue.
November 27, 2024
·
1 min read
·
Heather McKenzie
GLP-1
Novo’s Semaglutide Linked to Reduced Alzheimer’s Risk in Real-World Study
Researchers have linked Novo Nordisk’s semaglutide to a 40% to 70% reduction in the risk of Alzheimer’s disease diagnosis in a study of medical records from 1 million patients.
October 24, 2024
·
2 min read
·
Annalee Armstrong
Alzheimer’s disease
Lilly Lowers Brain Swelling With Modified Dosing of Alzheimer’s Drug Kisunla
Approved by the FDA in July to treat adults with early symptomatic Alzheimer’s disease, Eli Lilly’s Kisunla reduced the brain swelling of patients in a late-stage trial following an adjusted dosing regimen.
October 30, 2024
·
2 min read
·
Tristan Manalac
Alzheimer’s disease
Roche Trims Another Alzheimer’s Prospect, Ending UCB Collabortion
Roche drops a third Alzheimer’s candidate this year, terminating a partnership with UCB just four years after agreeing to work together on new treatments for the neurological disease.
October 22, 2024
·
1 min read
·
Annalee Armstrong
Alzheimer’s disease
Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s Readout
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington’s is ongoing, with early data expected later this year.
October 8, 2024
·
2 min read
·
Tristan Manalac
1 of 56,631
Next
